Physician profile
Allan I Silver
NPI 1699868810
$2,235.11
in general payments reported to CMS, 2019-2025
24 companies · $400 in 2025
The $400 reported for 2025 was more than what 75% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $752 · 2020: $116 · 2022: $305 · 2023: $311 · 2024: $352 · 2025: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,062.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,062.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $600.07 | 2022-2025 | Veozah |
| Abbvie INC. | $259.56 | 2019-2023 | Orilissa, Lo Loestrin Fe |
| Biogen, INC. | $219.58 | 2024-2025 | Zurzuvae |
| Pfizer INC. | $137.10 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $123.09 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $118.64 | 2019-2020 | |
| Evofem Biosciences, INC. | $99.52 | 2024-2025 | Solosec, Phexx, Phexxi |
| Coopersurgical, INC. | $82.86 | 2019-2024 | Paragard T 380a |
| Allergan, INC. | $77.72 | 2019 | |
| Exeltis, USA INC. | $72.59 | 2019-2022 | |
| Avion Pharmaceuticals | $63.12 | 2019-2020 | |
| Daiichi Sankyo INC. | $49.21 | 2019-2024 | Injectafer |
| Hologic Sales and Service, LLC | $46.80 | 2025 | Aptima, Fetal Fibronectin Enzyme Immunoassay |
| Mayne Pharma Commercial LLC | $41.96 | 2025 | |
| Lupin INC. | $40.55 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $31.17 | 2019 | |
| Organon LLC | $28.33 | 2023 | Nexplanon |
| Minerva Surgical, INC | $26.84 | 2019 | |
| Millicent US INC | $23.08 | 2025 | Femlyv |
| Myovant Sciences INC. | $22.93 | 2022 | |
| Vertical Pharmaceuticals, LLC | $18.75 | 2019 | |
| Amag Pharmaceuticals, INC. | $18.44 | 2019 | |
| Aspira Women'S Health INC | $17.60 | 2023 | Ova1 |
| Meditrina | $15.60 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allan Silver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.